Brief: Anthera Pharma says reached enrollment target in phase-3 trial with blisibimod
16/06/2015 22:02
June 16 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O : * Has reached enrollment target in chablis-sc1 phase 3 clinical trial with blisibimod * Says final data from the trial is expected in the second half of 2016 * Source text for Eikon ID:nGNXVDVCZa * Further company coverage ANTH.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman